172 related articles for article (PubMed ID: 32275456)
21. Nanosuspension of efavirenz for improved oral bioavailability: formulation optimization, in vitro, in situ and in vivo evaluation.
Patel GV; Patel VB; Pathak A; Rajput SJ
Drug Dev Ind Pharm; 2014 Jan; 40(1):80-91. PubMed ID: 23323843
[TBL] [Abstract][Full Text] [Related]
22. Lamotrigine loaded poly-ɛ-(d,l-lactide-co-caprolactone) nanoparticles as brain delivery system.
Ammar HO; Ghorab MM; Mahmoud AA; Higazy IM
Eur J Pharm Sci; 2018 Mar; 115():77-87. PubMed ID: 29341900
[TBL] [Abstract][Full Text] [Related]
23. Stability study and lyophilization of vitamin E-loaded nanocapsules prepared by membrane contactor.
Khayata N; Abdelwahed W; Chehna MF; Charcosset C; Fessi H
Int J Pharm; 2012 Dec; 439(1-2):254-9. PubMed ID: 23010283
[TBL] [Abstract][Full Text] [Related]
24. Efavirenz oral delivery via lipid nanocapsules: formulation, optimisation, and ex-vivo gut permeation study.
Varshosaz J; Taymouri S; Jahanian-Najafabadi A; Alizadeh A
IET Nanobiotechnol; 2018 Sep; 12(6):795-806. PubMed ID: 30104454
[TBL] [Abstract][Full Text] [Related]
25. Preparation of olmesartan medoxomil solid dispersion with sustained release performance by mechanochemical technology.
Zhang Q; Feng Z; Ren W; Zhao Y; Dushkin AV; Su W
Drug Deliv Transl Res; 2022 Mar; 12(3):589-602. PubMed ID: 33860449
[TBL] [Abstract][Full Text] [Related]
26. Poly (ε-caprolactone) nanocapsules for oral delivery of raloxifene: process optimization by hybrid design approach, in vitro and in vivo evaluation.
Aditya N; Ravi PR; Avula US; Vats R
J Microencapsul; 2014; 31(5):508-18. PubMed ID: 24697167
[TBL] [Abstract][Full Text] [Related]
27. Positively charged self-nanoemulsifying oily formulations of olmesartan medoxomil: Systematic development, in vitro, ex vivo and in vivo evaluation.
Beg S; Sharma G; Thanki K; Jain S; Katare OP; Singh B
Int J Pharm; 2015 Sep; 493(1-2):466-82. PubMed ID: 26211900
[TBL] [Abstract][Full Text] [Related]
28. Paliperidone-Loaded Nanolipomer System for Sustained Delivery and Enhanced Intestinal Permeation: Superiority to Polymeric and Solid Lipid Nanoparticles.
Helal HM; Mortada SM; Sallam MA
AAPS PharmSciTech; 2017 Aug; 18(6):1946-1959. PubMed ID: 27914041
[TBL] [Abstract][Full Text] [Related]
29. Primidone-loaded poly-epsilon-caprolactone nanocapsules: incorporation efficiency and in vitro release profiles.
Ferranti V; Marchais H; Chabenat C; Orecchioni AM; Lafont O
Int J Pharm; 1999 Dec; 193(1):107-11. PubMed ID: 10581427
[TBL] [Abstract][Full Text] [Related]
30. Screening of formulation variables for the preparation of poly(epsilon-caprolactone) nanocapsules containing the local anesthetic benzocaine.
Moraes CM; de Matos AP; Grillo R; de Melo NF; de Paula E; Dias Filho NL; Rosa AH; Fraceto LF
J Nanosci Nanotechnol; 2011 Mar; 11(3):2450-7. PubMed ID: 21449406
[TBL] [Abstract][Full Text] [Related]
31. In vitro and in vivo effects of morin on the intestinal absorption and pharmacokinetics of olmesartan medoxomil solid dispersions.
Surampalli G; Satla M; Nanjwade BK; Patil PA
Drug Dev Ind Pharm; 2017 May; 43(5):812-829. PubMed ID: 27487480
[TBL] [Abstract][Full Text] [Related]
32. Formulation Screening and Freeze-Drying Process Optimization of Ginkgolide B Lyophilized Powder for Injection.
Liu D; Galvanin F; Yu Y
AAPS PharmSciTech; 2018 Feb; 19(2):541-550. PubMed ID: 28849380
[TBL] [Abstract][Full Text] [Related]
33. Formulation and optimization of raloxifene-loaded solid lipid nanoparticles to enhance oral bioavailability.
Tran TH; Ramasamy T; Cho HJ; Kim YI; Poudel BK; Choi HG; Yong CS; Kim JO
J Nanosci Nanotechnol; 2014 Jul; 14(7):4820-31. PubMed ID: 24757949
[TBL] [Abstract][Full Text] [Related]
34. Formulation and characterization of atovaquone nanosuspension for improved oral delivery in the treatment of malaria.
Borhade V; Pathak S; Sharma S; Patravale V
Nanomedicine (Lond); 2014 Apr; 9(5):649-66. PubMed ID: 23927590
[TBL] [Abstract][Full Text] [Related]
35. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.
Sawant KK; Patel MH; Patel K
Drug Dev Ind Pharm; 2016; 42(5):758-68. PubMed ID: 26548349
[TBL] [Abstract][Full Text] [Related]
36. Improved oral bioavailability of repaglinide, a typical BCS Class II drug, with a chitosan-coated nanoemulsion.
Karami Z; Saghatchi Zanjani MR; Nasihatsheno N; Hamidi M
J Biomed Mater Res B Appl Biomater; 2020 Apr; 108(3):717-728. PubMed ID: 31187938
[TBL] [Abstract][Full Text] [Related]
37. Chitosan nanoparticles for intranasal delivery of olmesartan medoxomil: Pharmacokinetic and pharmacodynamic perspectives.
Hassan RH; Gad HA; El-Din SB; Shaker DS; Ishak RAH
Int J Pharm; 2022 Nov; 628():122278. PubMed ID: 36243325
[TBL] [Abstract][Full Text] [Related]
38. Solid Lipid Nanoparticles of Dronedarone Hydrochloride for Oral Delivery: Optimization, In Vivo Pharmacokinetics and Uptake Studies.
Gambhire VM; Gambhire MS; Ranpise NS
Pharm Nanotechnol; 2019; 7(5):375-388. PubMed ID: 31376827
[TBL] [Abstract][Full Text] [Related]
39. Preparation and enhanced oral bioavailability of cryptotanshinone-loaded solid lipid nanoparticles.
Hu L; Xing Q; Meng J; Shang C
AAPS PharmSciTech; 2010 Jun; 11(2):582-7. PubMed ID: 20352534
[TBL] [Abstract][Full Text] [Related]
40. Tocophersolan stabilized lipid nanocapsules with high drug loading to improve the permeability and oral bioavailability of curcumin.
Bapat P; Ghadi R; Chaudhari D; Katiyar SS; Jain S
Int J Pharm; 2019 Apr; 560():219-227. PubMed ID: 30776407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
